Pfizer slightly raised the lower end of its full-year revenue forecast after beating Wall Street estimates for second-quarter profit, driven by strong demand for blood thinner Eliquis. The U.S. drugmaker now expects annual sales of $60.5 billion to $62.5 billion, up from $59.5 billion to $62.5 billion forecast previously. On an adjusted basis, the company reported a profit of 77 cents per share, compared with analysts' estimates of 68 cents per share, according to data compiled by LSEG. Shares rose 1.8% to $25.5 in premarket trading.
Pfizer IncBeats profit estimates and raises full-year revenue forecast